The Authors: Dr Yuben Moodley is Associate Professor of Respiratory Medicine at the University of Western Australia with an interest in lung fibrosis and cellular therapies for lung disease. Dr Ursula Manuelpillai is Senior Research Fellow at the Monash Institute for Medical Research with an interest in placental stem cells. Dr Daniel Weiss is Associate Professor of Medicine at the University of Vermont and a leader in lung stem cell research.
Cellular therapies for lung disease: A distant horizon
Article first published online: 27 JAN 2011
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology
Volume 16, Issue 2, pages 223–237, February 2011
How to Cite
MOODLEY, Y., MANUELPILLAI, U. and WEISS, D. J. (2011), Cellular therapies for lung disease: A distant horizon. Respirology, 16: 223–237. doi: 10.1111/j.1440-1843.2010.01914.x
SERIES EDITOR: DARRYL KNIGHT
- Issue published online: 27 JAN 2011
- Article first published online: 27 JAN 2011
- Accepted manuscript online: 24 DEC 2010 09:55AM EST
- Received 18 December 2009; invited to revised 3 February 2010, 24 November 2010; revised 7 October 2010, 1 December 2010; accepted 2 December 2010.
- cell transplantation;
- cellular therapy;
- lung regeneration;
- stem cell
Lung diseases constitute a major global burden of health and are characterized by inflammation and chronic fibrosis resulting in a loss of gas exchange units. To date there has been no effective treatment to reverse these chronic inflammatory changes and tissue remodelling. Recently, stem cells have been shown to successfully treat animal models of lung disease. In addition, certain cells have demonstrated a capacity to differentiate into lung cells. Based on these preliminary data, there are clinical trials underway to examine the potential for cellular therapies in lung disease. Recently, there have been a variety of cell examined for both their immunomodulatory effects on the lung as well as their potential for differentiation into lung cells. These range from lung progenitor cells, circulating cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPS), placental stem cells and embryonic stem cells (ESCs). Several cell types demonstrate immunomodulatory effects including circulating cells, MSCs and placental stem cells. In addition, iPS, placental cells and ESCs have shown some capacity for differentiation.
Despite these major steps forward cellular therapy for lung diseases still faces challenges. Issues that need to be resolved include bioethical issues, the safety of cell transplantation, ideal routes of delivery, the timing and the specific indications that would make cellular therapy effective.